Skye Bioscience rises as it begins testing higher doses of obesity drug

Skye Bioscience

02/04/2026 12:45

** Shares of biotech firm Skye Bioscience SKYE.O rise 1.2% to $0.67 premarket

** Co says it has begun testing higher doses of its experimental obesity drug, nimacimab, in a new expansion study

** Adds the study will test 400 mg and 600 mg intravenous doses over 16 weeks to check safety and how the drug moves through the body, versus placebo

** Eight patients will be enrolled per dose group; the second group will start only if no safety issues emerge after four weeks - SKYE

** Earlier data showed a combination of nimacimab and semaglutide led to 22.3% average weight loss after 52 weeks, with no plateau - SKYE

** Co plans to report early data in Q4 this year and will refine upcoming trials after FDA feedback

** As of last close, stock down ~11% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))